ProfileGDS5678 / 1429006_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 30% 31% 33% 31% 30% 30% 30% 30% 30% 31% 48% 31% 31% 31% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7178430
GSM967853U87-EV human glioblastoma xenograft - Control 22.7012631
GSM967854U87-EV human glioblastoma xenograft - Control 32.7549233
GSM967855U87-EV human glioblastoma xenograft - Control 42.6451331
GSM967856U87-EV human glioblastoma xenograft - Control 52.6412330
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7452830
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7247230
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6777530
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6679730
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6822831
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1180648
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6707431
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6954931
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6926531